Ardent Biopharma is a next-generation biosimilars company developing monoclonal antibodies and therapeutic proteins using continuous manufacturing, AI/ML, and digital twin technology. By pursuing regulatory pathways that may waive Phase III efficacy trialsave and optimizing cost of goods, the company aims to deliver biosimilars at under 20% of originator prices. Its initial pipeline candidates, AB01 and AB02, are being developed through an exclusive partnership with a CDMO specializing in continuous biologics manufacturing.
Funding
Funding not disclosed
Founders
Product
Problem
Biosimilar development and manufacturing costs remain prohibitively high, limiting widespread patient access to life-saving biologic therapies. Traditional batch manufacturing and costly clinical efficacy trials drive up development expenses and final drug prices, particularly for complex monoclonal antibodies.
Solution
Ardent Biopharma is a next-generation biosimilar company leveraging recent advances in continuous manufacturing (CM), artificial intelligence, and machine learning to redefine cost efficiency in producing monoclonal antibodies and other therapeutic proteins. The company plans to seek regulatory approval using only pharmacokinetic and safety studies, capitalizing on anticipated waivers of Phase III clinical trials where scientific evidence demonstrates critical quality attributes match the reference product. Development and early-stage manufacturing are conducted with specialized CDMO partners, while Ardent retains ownership of product development, regulatory submissions, and future commercial manufacturing at its proprietary facility using production scales up to 1,000 L. By integrating digital twin technology and automated continuous processing, the company targets biosimilar pricing below 20% of originator products.
Target Audience
Primary customers are healthcare systems, payers, and patients seeking affordable biologic therapies, as well as regional marketing and sales partners that will commercialize Ardent's biosimilars across different markets.
Features
- Continuous manufacturing platform with highly productive perfusion cell lines designed for cost-of-goods optimization from lab through GMP scale
- Digital twin technology powered by AI/ML to enable automated, lights-off GMP manufacturing and unprecedented cost reductions
- Regulatory strategy pursuing waivers of Phase III efficacy trials based on thorough biosimilarity evidence, reducing development costs dramatically
- Proprietary development of both first- and second-wave biosimilars covering monoclonal antibody and therapeutic protein targets
- Exclusive partnership structure with a CDMO for drug substance activities, including cell line development, analytical testing, scale-up, and process performance qualification